



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Bemrist Breezhaler

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency's update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
Variation type IA /	A. ADMINISTRATIVE CHANGES - A.7	07/10/2025		Annex II and	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



EMA/VR/0000303707	Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted			PL	
Variation type IA / EMA/VR/0000244278	A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate	31/07/2025	N/A		

	used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted				
	B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted				
	B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/intermediate/or excipient - B.III.1.b.4 Deletion of certificates (in case multiple certificates exist per material) - Accepted				
	B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/intermediate/or excipient - B.III.1.b.2 New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer - Accepted				
	B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/				

	intermediate/or excipient - B.III.1.b.2 New certificate for a starting material/reagent/ intermediate/or excipient from a new or an already approved manufacturer - Accepted				
--	--	--	--	--	--